Ranbaxy Top brass reshuffled

New Delhi: Ranbaxy Laboratories Ltd yesterday announced a top-level restructuring, including internal reshuffles and appointments from outside the organisation.

Pointing out that the appointments are in line with the company's targeted revenues of $2 billion by 2007, a company statement said that the top management team now consists of 27 vice-presidents and three executive directors.

"These new positions have been created to provide leadership and focus in the critical areas of clinical research, global quality, sales and marketing, legal and secretarial, global corporate communications and public affairs, and other key disciplines requiring significant attention and top management expertise," the company said.

M Ramesh Adige, vice president for corporate affairs, has been elevated to the company's board while R. Sundar Rajan, from Wipro, has been taken in as vice president (legal).

Sundar Rajan was the corporate vice-president, legal and group general counsel in Wipro and "brings with him rich and varied experience in the legal and secretarial functions and a significant knowledge base in mergers and acquisitions," said Brian Tempest, CEO and managing director of Ranbaxy.

Additionally, seven senior executives of the company have been promoted as vice-presidents.

R Gowrishankar is now the vice-president (clinical research); Jim Meehan, who has been instrumental in setting up an extensive distribution system for Ranbaxy's expanding product portfolio in the US, is now the vice president (sales, marketing and distribution).

"This strengthens the company's generic sales and marketing initiative in the highly competitive North American market," adds the company statement.